The license, which Innovent’s Altruist business said is the first of its kind, positions the CDMO to support commercial ...
In this episode of Denatured, you'll hear from Jason Jones, head of global business development at Cellular Origins and ...
BioSpace’s Biopharma Job Market Report reveals early signs of recovery for 2026. A rise in job postings, a surge in contract ...
Industry leader Steve Ubl has served as PhRMA’s CEO for more than a decade, the longest tenure of any head of the trade group ...
Sidewinder Therapeutics’ bispecific antibody-drug conjugates target pairs of receptors found on cancer cells, which the ...
Gilead Sciences has inked three deals this year so far totaling $14.77 billion, a marked escalation of the company’s usual ...
Looking for a biopharma job in Texas? Check out the BioSpace list of 10 companies hiring life sciences professionals like you ...
Another bidder, which remains unidentified, dropped out of the bidding process. Analysts at William Blair now think it ...
The approval of Eli Lilly’s oral obesity drug officially ignites an intense competition with Novo Nordisk’s oral Wegovy; ...
"Your tenure has overseen a DESTRUCTION of shareholder value—a direct result of chronic operational shortcomings and failures ...
After a Phase 2 flop, Brinsupri exits the race to market for the chronic skin disease hidradenitis suppurativa, but other ...
Some bosses stretch you. Others make work more bearable. Both can earn your loyalty. Only one is building your future.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results